Proactive Investors - Run By Investors For Investors

Sareum Holdings says taking back control of cancer technology is “good news”

Tim Mitchell, chief executive of Sareum Holdings Plc (LON:SAR) tells Proactive the company took back the rights to Aurora +FLT3 kinase inhibitors from Hebei Medical University Biomedical Engineering Center in China.

He said: “The initial project did seem to work very well, good progress was made but then we hit a formulation issue, which proved very difficult to resolve.”

 
Meet Location Sciences Group PLC, Itaconix Plc, Shield Therapeutics PLC and WideCells Group at our event, London , 21 March 2019. Register here »
View full SAR profile View Profile

Sareum Holdings Plc Timeline

Big Picture
February 22 2019

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use